Study to Determine if Olmesartan Medoxomil Has the Potential to Benefit the Cardiovascular System in Terms of Arterial Protection

NCT00676845 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

133

Enrollment

INDUSTRY

Sponsor class

Conditions

Metabolic Syndrome
Hypertension

Interventions

DRUG: olmesartan medoxomil
DRUG: placebo
DRUG: olmesartan medoxomil
DRUG: olmesartan medoxomil

Sponsor

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company